We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

283 hedge funds and large institutions have $4.38B invested in Intra-Cellular Therapies Inc. in 2022 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 94 increasing their positions, 94 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 36

14% more capital invested

Capital invested by funds: $3.85B → $4.38B (+$534M)

3% more funds holding

Funds holding: 274 → 283 (+9)

0% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 94

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

20% less call options, than puts

Call options by funds: $16.9M | Put options by funds: $21M

Holders
283
Holders Change
+9
Holders Change %
+3.28%
% of All Funds
4.55%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.1%
New
48
Increased
94
Reduced
94
Closed
36
Calls
$16.9M
Puts
$21M
Net Calls
-$4.11M
Net Calls Change
-$6.53M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$88.1M
2
JP Morgan Chase
JP Morgan Chase
New York
+$65.7M
3
Citadel Advisors
Citadel Advisors
Florida
+$23.9M
4
BlackRock
BlackRock
New York
+$17.4M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$12.6M

Top Sellers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$56.7M
2
APM
Avidity Partners Management
Texas
-$45M
3
WA
Wasatch Advisors
Utah
-$25.2M
4
SC
Samlyn Capital
New York
-$25M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$23.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
SG
201
Stonnington Group
California
$244K -$10K -200 -4%
ONGA
202
O'Neil Global Advisors
California
$237K +$225K +4,487 New
Rafferty Asset Management
203
Rafferty Asset Management
New York
$236K -$12.7K -254 -5%
Nisa Investment Advisors
204
Nisa Investment Advisors
Missouri
$236K – – –
II
205
Inspire Investing
Idaho
$236K +$401 +8 +0.2%
Canada Life
206
Canada Life
Manitoba, Canada
$228K – – –
Neuberger Berman Group
207
Neuberger Berman Group
New York
$225K +$213K +4,260 New
RJFSA
208
Raymond James Financial Services Advisors
Florida
$222K +$210K +4,190 New
AWCI
209
Alpine Woods Capital Investors
New York
$212K -$25.1K -500 -11%
OSAM
210
O'Shaughnessy Asset Management
Connecticut
$210K +$199K +3,970 New
HSBC Holdings
211
HSBC Holdings
United Kingdom
$210K +$198K +3,954 New
MML Investors Services
212
MML Investors Services
Massachusetts
$208K +$197K +3,926 New
Susquehanna International Group
213
Susquehanna International Group
Pennsylvania
$203K -$1.54M -30,700 -89%
Russell Investments Group
214
Russell Investments Group
United Kingdom
$201K – – –
CJL
215
Cyrus J. Lawrence
New York
$188K – – –
Rockefeller Capital Management
216
Rockefeller Capital Management
New York
$188K +$3.71K +74 +2%
Osaic Holdings
217
Osaic Holdings
Arizona
$166K -$9.72K -194 -6%
ETC
218
Exchange Traded Concepts
Oklahoma
$142K +$17K +339 +14%
PA
219
Parallel Advisors
California
$133K -$150 -3 -0.1%
EIM
220
Essex Investment Management
Massachusetts
$114K +$108K +2,155 New
C
221
Covestor
United Kingdom
$111K +$10.5K +209 +11%
CSPIA
222
Cary Street Partners Investment Advisory
Virginia
$83.6K +$79.2K +1,580 New
US Bancorp
223
US Bancorp
Minnesota
$69K -$2.76K -55 -4%
BCM
224
Blume Capital Management
California
$66.2K – – –
BAM
225
Belpointe Asset Management
Nevada
$64.2K +$60.8K +1,214 New
7 8
9
10 11

ITCI Hedge Fund Activity: Q4 2022 in Review

283 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2022, worth a combined $4.38B — up 14% from $3.85B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new ITCI positions and 36 closed out — a net gain of 12 holders — while 94 added to existing stakes and 94 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $88.1M. The largest seller was Lord, Abbett & Co, cutting an estimated $56.7M.

  • 283 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2022, up from 274 in Q3 2022.
  • Funds reported $4.38B of Intra-Cellular Therapies Inc. stock for Q4 2022, up 14% quarter-over-quarter.
  • 48 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2022 and 36 closed out, a net change of +12 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q4 2022 was Fidelity Investments, an estimated $88.1M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q4 2022 was Lord, Abbett & Co, an estimated $56.7M sold.

Based on aggregated 13F filings for Q4 2022.